Gilteritinib in Isolated Breast Relapse of &lt;b&gt;&lt;i&gt;FLT3&lt;/i&gt;&lt;/b&gt; Positive Acute Myeloid Leukemia: A Case Report and Review of Literature

Arrigo, Giulia; D’Ardia, Stefano; Audisio, Ernesta; Cerrano, Marco; Freilone, Roberto; Giai, Valentina; Secreto, Carolina; Urbino, Irene; Frairia, Chiara

doi:10.1159/000524878

Cited by 4 publications

(1 citation statement)

References 25 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are few specific treatments for MS [ 11 ] and systemic therapy is usually recommended for treating this disease in patients with AML [ 12 ]. In recent years, considerable progress in the field of molecular genetics has provided new insights into MS, gradually transforming traditional chemotherapy into targeted therapies [ 13 – 16 ]. Venetoclax-based therapy was described as a very promising regimen in several case reports [ 17 – 20 ].…”

Section: Introductionmentioning

confidence: 99%

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Jian,

Cha,

Lin

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background The treatment of myeloid sarcoma (MS) is challenging and has not markedly improved patient prognosis. The introduction of venetoclax (VEN) has changed the treatment of MS, and venetoclax-based therapy has been described as very promising in several case reports. Methods In this retrospective study, we analyzed the treatment outcomes of 14 patients with MS treated with venetoclax-based therapy at The First Affiliated Hospital of Xiamen University from January 2020 to October 2023 Results The cohort consisted of 7 (50%) women and 7 (50%) men with an average age of 37.5 years. Four patients (28.6%) had isolated MS de novo, 2 (14.2%) were diagnosed synchronously with AML, and 8 (57.2%) had isolated extramedullary relapse. The most common sites for MS in our cohort were the skin and lung, followed by the spinal canal, soft tissue, bone and kidney. Five patients were affected at more than three sites. Nine patients received VEN in combination with azacytidine, and 5 patients received VEN in combination with other agents. The median number of venetoclax therapies administered was 2 cycles (range: 1–10 cycles). A response was observed in all patients included in the study, with 8 patients (57.2%) achieving a CR and 3 patients (21.4%) achieving a PR, corresponding to an ORR (including CR and PR) of 78.6%. The median follow-up time for all patients was 13 months (range 1–44 months), and the 1 year OS for all patients was 67.7%. Conclusions Venetoclax-based therapy shows excellent efficacy and safety in MS patients in the “real world” at a single institution, and a corresponding prospective study is needed to verify this conclusion.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Jian,

Cha,

Lin

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

Myeloid sarcoma: more and less than a distinct entity

Loscocco

Vannucchi

2023

Ann Hematol

View full text Add to dashboard Cite

Myeloid sarcoma (MS) is a distinct entity among myeloid neoplasms defined as a tumour mass of myeloid blasts occurring at an anatomical site other than the bone marrow, in most cases concomitant with acute myeloid leukaemia (AML), rarely without bone marrow involvement. MS may also represent the blast phase of chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). However, the clinical and molecular heterogeneity of AML, as highlighted by the 2022 World Health Organization (WHO) and International Consensus (ICC) classifications, indirectly define MS more as a set of heterogeneous and proteiform diseases, rather than a homogeneous single entity. Diagnosis is challenging and relies mainly on histopathology, immunohistochemistry, and imaging. Molecular and cytogenetic analysis of MS tissue, particularly in isolated cases, should be performed to refine the diagnosis, and thus assign prognosis guiding treatment decisions. If feasible, systemic therapies used in AML remission induction should be employed, even in isolated MS. Role and type of consolidation therapy are not univocally acknowledged, and systemic therapies, radiotherapy, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) should be considered. In the present review, we discuss recent information on MS, focusing on diagnosis, molecular findings, and treatments also considering targetable mutations by recently approved AML drugs.

show abstract

Gene Mutations and Targeted Therapies of Myeloid Sarcoma

Zhang

Chen

et al. 2023

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Gilteritinib in Isolated Breast Relapse of <b><i>FLT3</i></b> Positive Acute Myeloid Leukemia: A Case Report and Review of Literature

Cited by 4 publications

References 25 publications

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Myeloid sarcoma: more and less than a distinct entity

Gene Mutations and Targeted Therapies of Myeloid Sarcoma

Contact Info

Product

Resources

About